Patents by Inventor Robert A. Lenz

Robert A. Lenz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE
    Publication number: 20230020514
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 19, 2023
    Applicant: AMGEN INC.
    Inventors: Hong SUN, Eduardo DUNAYEVICH, Robert A. LENZ, Gabriel VARGAS
  • Methods for treating or preventing migraine headache
    Patent number: 11466090
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 11, 2022
    Assignee: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE
    Publication number: 20190256607
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 22, 2019
    Applicant: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • Methods for treating or preventing migraine headache
    Patent number: 10259877
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 16, 2019
    Assignee: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE
    Publication number: 20160311913
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: AMGEN INC.
    Inventors: Hong SUN, Eduardo DUNAYEVICH, Robert A. LENZ, Gabriel VARGAS
  • Azaadamantane derivatives and methods of use
    Patent number: 8802693
    Abstract: An embodiment relates to a nicotinic acetylcholine receptor ligand, a therapeutically suitable salt, prodrug, or a metabolite thereof, for the prevention and treatment of diseases and conditions that are mediated by nicotinic acetylcholine receptors, and methods of use thereof. Another embodiment is a method of administering a pharmaceutically effective amount of a nicotinic acetylcholine receptor ligand, a therapeutically suitable salt, prodrug, or a metabolite thereof, to a mammal in need thereof.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: August 12, 2014
    Assignee: AbbVie Inc.
    Inventors: Laura M. Gault, Robert A. Lenz, Ahmed A. Othman